Cerebrospinal fluid α-synuclein levels in Parkinson's disease - changed or unchanged?-Reference-Cited by-同舟云学术

Cerebrospinal fluid α-synuclein levels in Parkinson's disease - changed or unchanged?

Published:2013-12-16 Issue:3 Volume:21 Page:365-367
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Zetterberg H.¹²,Petzold M.³,Magdalinou N.²

Affiliation:

1. Clinical Neurochemistry Laboratory; Institute of Neuroscience and Physiology; The Sahlgrenska Academy at the University of Gothenburg; Mölndal Sweden

2. UCL Institute of Neurology; Queen Square; London UK

3. Centre for Applied Biostatistics, Occupational and Environmental Medicine; University of Gothenburg; Gothenburg Sweden

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.12326/fullpdf

Reference30 articles.

1. The diagnosis of Parkinson's disease;Tolosa;Lancet Neurol,2006

2. Alpha-synuclein in Lewy bodies;Spillantini;Nature,1997

3. Multiple-system atrophy: a new alpha-synuclein disease?;Gai;Lancet,1998

4. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma;El-Agnaf;FASEB J,2003

5. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein;Desplats;Proc Natl Acad Sci USA,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease;Acta Neuropathologica Communications;2018-11-26

2. L ongitudinal M easurements of C erebrospinal F luid B iomarkers in P arkinson's D isease;Movement Disorders;2016-02-16

3. Alpha-Synuclein as a Diagnostic Biomarker for Parkinson’s Disease;Methods in Pharmacology and Toxicology;2016

4. Advances in Biomarker Research in Parkinson’s Disease;Current Neurology and Neuroscience Reports;2015-12-29

5. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay;Molecular Neurodegeneration;2015-12